Cargando…
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), quickly spread throughout the world. In response to this global pandemic, a few vaccines were allowed for emergency...
Autores principales: | Uddin, Mohammad N., Roni, Monzurul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473088/ https://www.ncbi.nlm.nih.gov/pubmed/34579270 http://dx.doi.org/10.3390/vaccines9091033 |
Ejemplares similares
-
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
por: Oude Blenke, Erik, et al.
Publicado: (2023) -
Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines
por: Young, Rachel E., et al.
Publicado: (2022) -
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022) -
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
por: Schoenmaker, Linde, et al.
Publicado: (2021) -
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
por: Liu, Ting, et al.
Publicado: (2022)